Predictive Value of Excision Repair Cross-complementing Rodent Repair Deficiency Complementation Group 1 and Ovarian Cancer Risk

This study was undertaken to examine whether there is an association between excision repair cross-complementation group 1 (ERCC1) and xeroderma pigmentosum D (XPD) protein expression levels and response to platinum-based chemotherapy in epithelial ovarian cancer (EOC). The study cohort consisted of 91 consecutive patients suffering from stage III or IV disease of primary EOC from 1999 to 2004 at the Women's Hospital, School of Medicine, Zhejiang University. There were 36 sensitive cases of serous ovarian cancer, 27 resistant cases of serous ovarian cancer, 15 cases of clear cell cancer, and 13 cases with serous ovarian cancer receiving neoadjuvant chemotherapy. The ovarian tissue microsections were stained by standard immunohistochemical techniques to show ERCC1 and XPD protein expression levels. In resistance group of serous ovarian cancer, ERCC1 and XPD protein expression levels were significantly higher than those of sensitivity group, and after receiving neoadjuvant chemotherapy, they showed 23% and 32% higher than before. Meanwhile, their levels of clear cell cancer group were significantly higher than serous ovarian cancer group's. Upregulation of ERCC1 and XPD protein expression was associated with resistance process to platinum-based chemotherapy in advanced EOC. This study provided evidence that differences of nucleotide excision repair–related genes expression may have an effect on the observed differences in clinical behavior of EOC

Download Full-text

Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-014-1758-4 ◽

2014 ◽

Vol 140 (12) ◽

pp. 2107-2117 ◽

Cited By ~ 8

Author(s):

Anqi Yao ◽

You Wang ◽

Xiaohong Peng ◽

Rong Ye ◽

Qiaoli Wang ◽

...

Keyword(s):

Gastric Cancer ◽

Predictive Value ◽

Excision Repair ◽

Meta Analysis ◽

Complementation Group ◽

Platinum Based Chemotherapy ◽

Group 1

Download Full-text

Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy

Cancer Biomarkers ◽

10.3233/cbm-170817 ◽

2018 ◽

Vol 21 (4) ◽

pp. 875-881 ◽

Cited By ~ 1

Author(s):

Dong Wang ◽

Juan Zhou ◽

Jihua Zheng ◽

Jiang Zhang ◽

Yaoming Chen ◽

...

Keyword(s):

Nasopharyngeal Carcinoma ◽

Predictive Value ◽

Concurrent Chemoradiotherapy ◽

Excision Repair ◽

Complementation Group ◽

Group 1

Download Full-text

ERCC1-Positive Circulating Tumor Cells in the Blood of Ovarian Cancer Patients as a Predictive Biomarker for Platinum Resistance

Clinical Chemistry ◽

10.1373/clinchem.2014.224808 ◽

2014 ◽

Vol 60 (10) ◽

pp. 1282-1289 ◽

Cited By ~ 56

Author(s):

Jan Dominik Kuhlmann ◽

Pauline Wimberger ◽

Agnes Bankfalvi ◽

Thomas Keller ◽

Sarah Schöler ◽

...

Keyword(s):

Ovarian Cancer ◽

Cell Surface ◽

Cancer Patients ◽

Independent Predictor ◽

Excision Repair ◽

Complementation Group ◽

Primary Diagnosis ◽

Platinum Resistance ◽

Ercc1 Expression ◽

Group 1

Abstract BACKGROUND Platinum resistance constitutes one of the most recognized clinical challenges for ovarian cancer. Notably, the detection of the primary tumor-based excision repair cross-complementation group 1 (ERCC1) protein by immunohistochemistry was recently shown to be inaccurate for the prediction of platinum resistance. On the basis of the previous finding that circulating tumor cells (CTC) in the blood of ovarian cancer patients are prognostically significant, and given our hypothesis that the negative prognostic impact of CTC may arise from a cellular phenotype associated with platinum resistance, we asked whether expression of the excision repair cross-complementation group 1 (ERCC1) gene in the form of the ERCC1 transcript in CTC may be a suitable blood-based biomarker for platinum resistance. METHODS The presence of CTC was analyzed by immunomagnetic CTC enrichment (n = 143 patients) targeting the epithelial epitopes epithelial cell adhesion molecule (EPCAM) (also known as GA733-2) and mucin 1, cell surface associated (MUC1), followed by multiplex reverse-transcription PCR to detect the transcripts EPCAM, MUC1, and mucin 16, cell surface associated (MUC16) (also known as CA125), including ERCC1 transcripts in a separate approach. ERCC1 expression in primary tumors was comparatively assessed by immunohistochemistry, using the antibody 8F1. RESULTS At primary diagnosis, the presence of CTC was observed in 14% of patients and constituted an independent predictor of overall survival (OS) (P = 0.041). ERCC1-positive CTC (ERCC1+CTC) were observed in 8% of patients and constituted an independent predictor, not only for OS but also for progression-free survival (PFS) (P = 0.026 and P = 0.009, respectively). More interestingly, we discovered the presence of ERCC1+CTC at primary diagnosis to be likewise an independent predictor of platinum resistance (P = 0.010), whereas ERCC1 expression in corresponding primary tumor tissue predicted neither platinum resistance nor prognosis. CONCLUSIONS The presence of ERCC1+CTC can serve as a blood-based diagnostic biomarker for predicting platinum resistance at primary diagnosis of ovarian cancer.

Download Full-text